Ozempic Lawsuits Heat Up - Novo Nordisk and Eli Lilly Move to Dismiss Claims
Defendants in the Ozempic and GLP-1 receptor agonist multidistrict litigation (MDL) have made their first big move—filing a motion to dismiss several claims in the plaintiffs’ master complaint. Their target? 12 out of 17 claims, primarily those alleging deceptive marketing and consumer fraud. Notably, they aren’t touching the core failure-to-warn claims—because they know that’s a losing battle.
This is a classic defense play: whittle down the case before tackling the real issue—whether Novo Nordisk and Eli Lilly misrepresented the severe gastrointestinal risks of GLP-1 medications like Ozempic and Mounjaro. While narrowing the scope of litigation may seem like a strategic win for the defense, it likely won’t derail the lawsuits in any meaningful way. The overwhelming evidence of misrepresentation and harm remains front and center, and these companies will have to answer for it.
Just as Novo Nordisk and Eli Lilly attempt to dodge certain claims, fresh research is adding fuel to the fire. A recent study published in JAMA Otolaryngology–Head & Neck Surgery found a significantly increased risk of thyroid cancer in patients who initiated GLP-1 receptor agonist therapy within the first year. While correlation doesn’t equal causation, and increased medical surveillance could play a role, this study adds yet another layer of concern to the growing list of potential risks associated with these drugs.
This isn’t an isolated issue. Another January 2025 study has highlighted additional health risks linked to GLP-1 medications, including kidney stones, arthritis, fainting, and even drug-induced pancreatitis. While these drugs have been hailed as revolutionary for diabetes and weight loss, their side effect profile continues to raise serious red flags.
These lawsuits are not just about warning labels—they're about accountability. Patients relied on these medications to improve their health, only to face severe, life-altering complications. Novo Nordisk and Eli Lilly pushed these drugs aggressively, downplaying risks and ignoring early warning signs. Now, they’re scrambling to limit their legal exposure.
As the litigation progresses, we expect more evidence to surface, reinforcing what many plaintiffs already know: Ozempic and similar drugs are not the miracle cures they were made out to be. If you or a loved one have suffered serious complications after using GLP-1 medications, now is the time to step forward.
Stay tuned for more updates!
— LCA Insights! Team